NRC provides contribution funding for the operation, mantenance and enhancement of the Facility. The TRIUMF facility houses a particle accelerator, reffered to as a cyclotron, that produces beams of...
Federal spending by National Research Council Canada
65,866 records totalling $10,357,894,585.31 CAD, from official Government of Canada open data.
Embed this chart
Where the money flows
Planned vs. actual spending
What Parliament authorised this organization to spend versus what it actually spent, across all its votes. Source: Public Accounts of Canada (via GC InfoBase). This covers the organization's entire budget, not just the grants and contracts listed below.
| Fiscal year | Authorised | Spent | Used |
|---|---|---|---|
| 2024-2025 | $1,934,511,287 | $1,708,014,071 | 88.3% |
| 2023-2024 | $1,819,033,002 | $1,525,980,654 | 83.9% |
| 2022-2023 | $1,728,823,008 | $1,470,756,978 | 85.1% |
| 2021-2022 | $1,773,220,811 | $1,436,309,315 | 81.0% |
| 2020-2021 | $1,976,688,437 | $1,648,655,313 | 83.4% |
| 2019-2020 | $1,366,591,136 | $1,214,601,865 | 88.9% |
| 2018-2019 | $1,445,828,252 | $1,145,203,852 | 79.2% |
| 2017-2018 | $1,286,842,890 | $1,016,523,436 | 79.0% |
| 2016-2017 | $1,307,620,850 | $1,048,740,465 | 80.2% |
| 2015-2016 | $1,143,964,849 | $945,077,595 | 82.6% |
Did it deliver? (2024-2025 results report)
Every department sets measurable performance targets and reports against them. Source: Departmental Results Reports via GC InfoBase — the department's own self-reported scorecard.
51
of 70 targets met
19
targets not met
0
not yet measurable or unavailable
See missed targets
-
Number of patents issued to the NRC
Target: — · Actual: 99.0
-
Revenue earned from clients and collaborators
Target: — · Actual: 69500000.0
-
Revenue earned from all external research clients
Target: — · Actual: 24200000.0
-
Citation score of Aquatic and Crop Resource Development generated publications relative to world average
Target: — · Actual: 1.12
-
Number of patent applications filed
Target: — · Actual: 1.0
NRC provides contribution funding for the operation, mantenance and enhancement of the Facility. The TRIUMF facility houses a particle accelerator, reffered to as a cyclotron, that produces beams of...
NRC provides contribution funding for the operation, mantenance and enhancement of the Facility. The TRIUMF facility houses a particle accelerator, reffered to as a cyclotron, that produces beams of...
NRC provides contribution funding for the operation, mantenance and enhancement of the Facility. The TRIUMF facility houses a particle accelerator, reffered to as a cyclotron, that produces beams of...
NRC provides contribution funding for the operation, mantenance and enhancement of the Facility. The TRIUMF facility houses a particle accelerator, reffered to as a cyclotron, that produces beams of...
NRC provides contribution funding for the maintenance and operation of the BMC facility in a constant Good Manufacturing Practice (GMP)-readiness state to respond to pandemic and other health emergenc...
Canada's contribution to the SKA Organisation for the pre-construction design phase of the Square Kilometre Array Observatory
The Gemini Facilities consist of two identical optical-infrared telescopes with a primary mirror diameter of 8m, associated instruments and equipment, anciliary buildings, and support services related...
Facilitate the establishment of a Canadian regional centre that provides Canadian astronomers access to data from the SKA and other astronomy facilities. Provide dedicated storage, computing capacity...
ALMA is a large reconfigurable array of 66 parabolic-dish radio astronomy telescopes. The facility includes associated instruments and equipment, ancillary buildings, and support services related to t...
The group will undertake a national scope joint research driven incubator project, to amplify the universities’ existing incubator facilities and to create an expansive technology, company and job-cre...
The objective of the project is to build an integrated incubation and acceleration program, which will provide high potential SMEs from Eastern Ontario with a graduated pathway to market. The project...
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...
Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.